Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership
Bristol-Myers Squibb is a Strong Buy at current levels, with a $54 price target and attractive 5.2% dividend yield. The company's innovative growth portfolio is gaining traction, offsetting legacy ...
Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good
Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Bristol Myers expects mid to high-single-digit sales growth for Opdivo and Qvantig in 2025 as approvals and launches gain momentum.
7 Big Yields From The Beat-Up Healthcare Sector
Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers Squibb is trading at a generational bargain, near 7x earnings, with a compelling 5.6% dividend yield and strong cash flow. Recent Q2 results beat expectations, and management is focus...
Bristol-Myers Squibb: Buy The Weakness
Bristol-Myers Squibb faces political pressure on U.S. drug prices, but I see the risk as manageable given its strong fundamentals. The company's growth portfolio now exceeds half of revenue, offset...
Bristol-Myers Squibb: Declines Have Gone Too Far
Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum. Despite margin compression and profitability ...
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising ...
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappoi...
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Nee...
PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)--Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical.
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
According to Yahoo Finance, the average annual percentage yield for high-yield money market accounts is currently around 4.30%, with some banks offering rates exceeding 5.00%.
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Bristol Myers Squibb is undervalued despite the looming patent cliff, as its robust pipeline and strong cash flow position it for future growth. The impact of Eliquis' patent expiry is overstated, ...
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
Related Companies